Vertex Pharmaceuticals Incorporated today announced that key data on sustained viral response (SVR) rates in both treatment-naive and treatment-failure genotype 1 hepatitis C (HCV) patients who received telaprevir-based treatment regimens will be presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), October 31 -- November 4, 2008 in San Francisco. In addition, week 4 and week 12 data from the C208 study exploring a twice-daily telaprevir dosing regimen in 160 genotype 1 HCV patients will be presented. A total of six abstracts related to Vertex's HCV protease inhibitor telaprevir clinical program were accepted for presentation. The abstracts are being published today and will be available online at the AASLD website www.aasld.org (you need to be a member of aasld to access the abstracts)
Telaprevir-Based Therapy in Treatment-Failure HCV Patients
1 - PROVE 3 Interim Analysis
A Phase 2b Study of Telaprevir with Peginterferon-Alfa-2a and Ribavirin in Hepatitis C Genotype 1 Null and Partial Responders and Relapsers Following a Prior Course of Peginterferon-Alfa-2a/b and Ribavirin Therapy:
PROVE 3 Interim Results will be presented in an oral session on Tuesday, November 4
2 - Study 107 Interim Analysis
A Study of Telaprevir Combined with Peginterferon-Alfa-2a and Ribavirin in Subjects with Well-Documented Non-Response or Relapse after Previous Peginterferon-Alfa-2a and Ribavirin Treatment:
Interim Analysis will be presented at a poster session on Tuesday, November 4
3 - Telaprevir-Based Therapy in Treatment-Naive HCV Patients
PROVE 2 Final Results
Telaprevir in Combination with Peginterferon-Alfa-2a with or without Ribavirin in the Treatment of Chronic Hepatitis C:
Final Results of the PROVE 2 Study will be presented in an oral session on Tuesday, November 4.
4 -Interim Analysis -- Twice-Daily Telaprevir Exploration
Phase 2 Study of Telaprevir Administered q8h or q12h with Peginterferon-Alfa-2a or -Alfa-2b and Ribavirin in Treatment-Naive Subjects with Genotype 1 Hepatitis C:
Week 4 Interim Results will be presented at a poster session on Tuesday, November 4
Additional Telaprevir Abstracts at AASLD
5 - Viral Responses in African-Americans, Latinos and Caucasians in the US Phase 2 Study (PROVE 1) of Telaprevir with Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Genotype 1-infected Subjects with Hepatitis C will be presented at a poster session on Tuesday, November 4
6 - Cleavage Sites During Treatment with Telaprevir, Peg-IFN-Alfa-2a, and Ribavirin in Phase II Studies of Treatment-NaAve HCV Genotype 1-Infected Patients" will be presented at a poster session on Tuesday, November 4 from 8:00 a.m. to 12:30 p.m. PST. The authors of the study are E. Z. Zhang, D. J. Bartels, J. Sullivan, M. Marcial, J. Dorrian, A. Tigges, A. D. Kwong and T. L. Kieffer.
About Telaprevir
Telaprevir (VX-950) is an investigational oral inhibitor of HCV protease, an enzyme essential for viral replication, and is one of the most advanced investigational antiviral agents in development that specifically targets HCV. Telaprevir is in Phase 3 clinical trials in treatment-naAve and treatment-failure patients.
